



Oramed Pharmaceuticals Inc.
**Suite 228, 1185 Avenue of
the Americas**
New York, NY 10036
Phone: 1 844 9 ORAMED
www.oramed.com

COMPANY OVERVIEW

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for variety of additional treatment indications to address multi-billion dollar markets
- Recently completed recruitment of primary cohort in 90-day HbA1c study of ORMD-0801 for oral insulin; this is Oramed's final pivotal phase IIb study, a prerequisite for phase III; data expected year-end 2019
- Based on clinical trials to date, Oramed's lead product, oral insulin, has potential to be the first commercial oral insulin capsule
- Robust patent portfolio covering oral delivery, methods of proteins, insulin and GLP-1

EQUITY OVERVIEW

(as of 8/1/2019)

Nasdaq/TASE: ORMP

Price: \$3.63

Market Cap: \$63.102M

52 Week Range: \$2.78-\$5.36

Avg. Daily Volume (90 day):
43.9K

Shares Outstanding: 17.4 M

Cash & Investments: \$40.8M (as
of 2/28/19)

ANALYST COVERAGE

- H.C. Wainwright & Co.
- B. Riley FBR
- Zacks
- Frost & Sullivan

BETTER WAY TO TREAT DIABETES

1 in 11 adults

on the planet has diabetes

**1 healthcare
in 8**
is spent on diabetes

**every
6 SECONDS**
**1 adult dies
from diabetes**
4M deaths in 2017

INVESTMENT HIGHLIGHTS

Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed's unique platform technology enables small proteins such as insulin to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and could therefore eliminate the many side effects of injection delivery to the bloodstream. Oramed believes that oral administration of current injection-only therapies for conditions including diabetes, offers clear benefits including increased compliance and safety, fewer side effects and greater comfort for patients.

Addressing \$70 Billion Market with Oral Formulations

Roughly \$70 billion worth of drugs and vaccines are currently delivered via injections. This includes the diabetes market where \$24 billion of insulin and \$6 billion of GLP-1 analogs were sold globally in 2017. The vaccine market size was approximately \$33 billion in 2015 and is expected to surpass \$77 billion by 2024.

Oral Treatment has the potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment, in this case by lowering nighttime glucose, can potentially slow disease progression and delay late-stage complications. Oramed recently concluded a successful Phase IIb study of ORMD-0801 which met its primary endpoints and showed that the drug reduced nighttime glucose levels. In May 2019, Oramed completed recruitment in a 90-day HbA1c study of ORMD-0801, designed to identify the optimal dose and a prerequisite for Phase III. Oramed is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801, which would grant a full 12 years of marketing exclusivity if approved.

Oral GLP-1 Analog to Stimulate Insulin Production in Type 2 Diabetes

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. It is beneficial to type 2 diabetic patients by promoting weight loss and decreasing blood sugar. GLP-1 analogs are currently available only via injection. Oramed's ORMD-0901, an oral GLP-1 analog completed two small ex-US clinical trials with encouraging results and a PK study in healthy subjects under an IND in the US.